Clinical Trial Update: 16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients [Phase 4]

View source ↗

Summary

A Phase 4 interventional study evaluating titration and dose/efficacy of Exelon (rivastigmine) in Chinese patients with Alzheimer's disease was completed, with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Exelon (rivastigmine)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Alzheimer's Disease | Phase 4 | Status: COMPLETED | Results posted: 2017-02-13